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Background: To detect genes correlated with hepatocellular carcinoma (HCC), we developed a triple combination
array consisting of methylation array, gene expression array and single nucleotide polymorphism (SNP) array
analysis.
Methods: A surgical specimen obtained from a 68-year-old female HCC patient was analyzed by triple combination
array, which identified doublecortin domain-containing 2 (DCDC2) as a candidate tumor suppressor gene of HCC.
Subsequently, samples from 48 HCC patients were evaluated for their DCDC2 methylation and expression status
using methylation specific PCR (MSP) and semi-quantitative reverse transcriptase (RT) PCR, respectively. Then, we
investigated the relationship between clinicopathological factors and methylation status of DCDC2.
Results: DCDC2 was revealed to be hypermethylated (methylation value 0.846, range 0–1.0) in cancer tissue,
compared with adjacent normal tissue (0.212) by methylation array in the 68-year-old female patient. Expression
array showed decreased expression of DCDC2 in cancerous tissue. SNP array showed that the copy number of
chromosome 6p22.1, in which DCDC2 resides, was normal. MSP revealed hypermethylation of the promoter region
of DCDC2 in 41 of the tumor samples. DCDC2 expression was significantly decreased in the cases with methylation
(P = 0.048). Furthermore, the methylated cases revealed worse prognosis for overall survival than unmethylated
cases (P = 0.048).
Conclusions: The present study indicates that triple combination array is an effective method to detect novel
genes related to HCC. We propose that DCDC2 is a tumor suppressor gene of HCC.
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Hepatocellular carcinoma (HCC) is currently the fifth
most common malignancy worldwide [1], and its overall
incidence is steadily rising. In spite of the therapeutic
options for HCC such as hepatic resection [2], radiofre-
quency ablation [3], transcatheter arterial chemoembo-
lization [4], and sorafenib [5], the prognosis of patients with
advanced HCC remains poor [6,7]. Therefore, research to* Correspondence: snomoto@med.nagoya-u.ac.jp
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reproduction in any medium, provided the orclarify the mechanisms of hepatocarcinogenesis is urgently
required [8].
Gene expression microarray analysis has revealed
many cancer-related genes in HCC [9]. This method en-
ables the expression status of all genes to be investigated
simultaneously [10]. Furthermore, single nucleotide po-
lymorphism (SNP) arrays have made it possible to detect
copy number changes as well as copy-neutral loss of het-
erozygosity (LOH) [11]. Recently we developed a double
combination array analysis consisting of gene expression
array and SNP array analysis, and reported a number of
tumor suppressor genes in HCC [12-17]. In thesel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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promoter region of these genes downregulated gene
expression, causing HCC progression. In addition to
this double combination array analysis, we obtained
further data from the same specimens using methyla-
tion array analysis to make this association of DNA
methylation more conclusive. We named it triple com-
bination array analysis; this method seems to be an ef-
ficient procedure for the detection of tumor suppressor
genes of HCC [18].
Doublecortin domain-containing 2 (DCDC2) is a can-
didate tumor suppressor gene detected by this triple
combination array analysis. This gene encodes a member
of the doublecortin family [19], and contains two double-
cortin domains. The doublecortin domain has been dem-
onstrated to bind tubulin and enhance microtubule
polymerization [19,20], and mutations in this gene have
been associated with dyslexia [21-24]. However, there are
only a few reports of the relationship between DCDC2
and cancer [25]. In addition, no previous study has
researched the role of DCDC2 in HCC. Although it had
been considered that DCDC2 gene had an impotrtant role
in neuroendocrine systems, the expression of the gene
was reported in GeneCards relatively strongest in liver in
whole human organs including brain. Therefore, we se-
lected this gene for this study, because we predicted the
gene might have some role in liver.
Methods
Sample collection and DNA preparation
Nine HCC cell lines (HepG2, Hep3B, HLE, HLF, HuH1,
HuH2, HuH7, PLC/PRF-5 and SK-Hep1) were obtained
from the American Type Culture Collection (Manassas,
VA, USA). The cell lines were cultured in RPMI-1640
supplemented with 10% fetal bovine serum, and incu-
bated in 5% CO2 at 37°C.
A 68-year-old woman with chronic hepatitis C was di-
agnosed with HCC in the right lobe and underwent liver
resection. Specimens of her tumor and adjacent non-
tumorous tissues were excised, and total RNA and DNA
were extracted. Total RNA was sent to the manufacturer
of Affymetrix to prepare it for expression array analysis.
Genomic DNA was used for a SNP-Chip array, and
bisulfite-converted DNA was used for the Ilumina
Infinium HumanMethylation 27 BeadChip (Illumina,
San Diego, CA, USA). The tumor was pathologically
confirmed as HCC. RNA and DNA of tumor samples
were extracted from an area consisting of >80% cancer-
ous cells.
HCC tissue (HTs) and normal tissue (NTs) samples
were obtained from 48 patients (43 males, five females)
who underwent liver resection at Nagoya University
Hospital, Nagoya, Japan between 1994 and 2001. Thepatients were aged from 39 to 77 years (mean ± SD, 62.4 ±
7.9 years). Thirty-eight patients had hepatitis C and
seven had hepatitis B. The median duration of follow-up
was 80.7 months (range 15.2–213.1 months). All tissues
were reviewed pathologically to confirm the diagnosis of
HCC. Written informed consent, as required by the in-
stitutional review board, was obtained from all pa-
tients. The tissue samples were immediately frozen in
liquid nitrogen and stored at −80°C until required.
Genomic DNA was obtained from the tissue samples
by proteinase K digestion, followed by phenol/chloro-
form extraction.
RNA isolation, microarray and gene chip affymetrix
procedures
The expression array and SNP array were performed, as
previously described [12-17], using total RNA and DNA
extracted from the 68-year-old woman’s tissue samples.
Methylation array platform
The Illumina Infinium HumanMethylation27 BeadChip
protocol requires 500 ng to 1 μg of bisulfite-converted
DNA [26]. Of the approximately 28 million CpG sites
found throughout the haploid human genome, Illumina
initially designed Infinium methylation probes for 27,578
CpG sites located in promoter regions (up to 1 kb up-
stream or 500 bp downstream of the transcription start
sites). Of these, 27,324 CpG sites relate to 14,475 consensus
coding sequences, including around 1000 cancer-associated
genes, and 254 CpG sites relate to approximately 100
micro-RNA genes. The probes were preferentially
selected to occur within CpG islands using the NCBI
“relaxed” definition of a CpG island: CpG islands identi-
fied bioinformatically with a CpG content of >50% and
an observed/expected ratio of >0.6 [27].
Bisulfite-converted DNA is then whole-genome ampli-
fied, enzymatically fragmented, and hybridized to the
array. During hybridization, the bisulfite-converted DNA
anneals to methylation-specific probes on the chip. Each
CpG locus is represented by two bead types, one of
which is specific to the methylated state and the other is
specific to the unmethylated state, which is directly re-
lated to the underlying sequence change catalyzed dur-
ing bisulfite conversion. Therefore, for each CpG site, a
possible C/T variant can be assayed through the single-
base extension step, which is possible because of the
ability to hybridize to either the “protected” methylated
cytosine or the converted (unmethylated) thymine.
After hybridization, a single-base extension step is car-
ried out using a multi-layer staining process, as de-
scribed below. The BeadChip is then scanned on the
Illumina iScan and the resulting “idat” files are analyzed
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analysis is a β-value for each CpG site. This is a continu-
ous value between 0 and 1 where 0 = 0% methylation and
1 = 100% methylation at a given CpG site. Therefore, this
assay enables quantitative analysis of methylation at indi-
vidual CpG sites.
Reverse transcription-polymerase chain reaction (RT-PCR)
DCDC2 mRNA expression was analyzed by semi-
quantitative RT-PCR and real-time RT-PCR. Total RNA
(10 μg) isolated from nine HCC cell lines, primary HTs
and NTs were used to generate cDNAs. The resulting
cDNAs were then amplified by PCR primers for DCDC2
(sense, 5′- GCT TCA GGA GCC GTG CAC TA -3′ in
exon 4); antisense 5′- CCC CGC TCC TCA GAG TGA
TT -3′ in exon 5), which amplified a 146-bp product.
Initial denaturation at 94°C for 5 min was followed by
amplification consisting of 35 cycles of 94°C for 10 s, 60°C
for 8 s, and 72°C for 6 s. RT-PCR of beta-actin was per-
formed to confirm equal amounts of cDNA was used as
templates. Each PCR product was loaded directly onto 3%
agarose gels, stained with ethidium bromide, and visual-
ized under UV illumination.
Real-time quantitative RT-PCR analysis
PCR was performed with the SYBR Green PCR Core Re-
agents kit (Perkin-Elmer Applied Biosystems, Foster
City, CA, USA) under the following conditions: 1 cycle
at 95°C for 10 s, followed by 40 cycles at 95°C for 5 s
and at 60°C for 30 s. SYBR Green emission was detected
in real-time with an ABI prism 7000 Sequence Detector
(Perkin-Elmer Applied Biosystems). The primers used in
PCR were the same as those described above for RT-
PCR. For standardization, the expression of GAPDH was
quantified in each sample. Quantitative RT-PCR was
performed at least three times, including negative con-
trols without template. The expression of DCDC2 was
normalized for that of GAPDH in each sample.
Methylation-specific PCR (MSP)
DNA from HCC cell lines, HTs and NTs were subjected
to bisulfite treatment. Briefly, 2 μg of DNA was dena-
tured by NaOH and modified by sodium bisulfite. DNA
samples were then purified using the Wizard purification
resin (Promega Corp., Madison, WI, USA), treated with
NaOH, precipitated with ethanol, and resuspended in
water. Primer pairs were used to detect methylation
(sense, 5′- AGG TCG TTG GGA TAG CGG AG -3′;
antisense, 5′- TCA TCT TCC CCG CTA ACC GC -3′;
73-bp product) and non-methylation (sense, 5′- GGG
TGT GGT GAG GTT GTT GG -3′; antisense, 5′- CTT
CCC CAC TAA CCA CCA CC -3′; 79-bp product) of
the DCDC2 promoter region near exon 1. The MSP andunmethylated-specific PCR (UNMSP) amplification consis-
ted of denaturation at 94°C for 5 min followed by 35 cycles
at 94°C for 8 s, 60°C for 5 s, and 72°C for 3 s. The PCR
products were loaded directly onto 3% agarose gels,
stained with ethidium bromide, and visualized under UV
illumination.
Sequence analysis
Bisulfite-treated genomic DNA obtained from HCC cell
lines was sequenced and PCR was performed in all cases.
We performed semi-nested PCR to gain adequate prod-
ucts for TA cloning. PCR amplification consisted of de-
naturation at 94°C for 3 min followed by 35 cycles of 94°C
for 10 s, 52°C for 10 s and 72°C for 20 s with primer pairs
(sense 5′- TTT AGT GTT TTT TTT GGG TG -3′; anti-
sense, 5′ - CTA AAC ACC TTC TTC TCA TG -3′ ;
312-bp product). The products were used as templates of
subsequent PCRs with primer pairs consisting of the same
sense, and different antisense (antisense, 5′- AAC AAA
TAA CTA AAC CTA AC -3′; 219-bp product). The PCR
products were subcloned into a TA cloning vector
(Invitrogen, Carlsbad, CA, USA). Six cloning samples were
picked out from two HCC cell lines (HuH2 and SK-Hep1).
Each DNA clone was mixed with 3 μl of the specific pri-
mer (M13) and 4 μl of Cycle Sequence Mix (ABI PRISM
Terminator v1. 1 Cycle Sequencing Kit; Applied Bio-
systems, Foster City, CA, USA). Samples were then
subjected to the following cycling conditions: 95°C for
30 s followed by 25 cycles of 96°C for 10 s, 50°C for 5 s,
and 60°C for 4 min, and then purified by ethanol precipi-
tation. Sequence analysis was carried out using an Applied
Biosystems ABI310, and sequence electropherograms
were generated using ABI Sequence Analysis software ver-
sion 3.0.
5-Aza-2′-deoxycytidine (5-aza-dC) treatment
To confirm that promoter hypermethylation was respon-
sible for silencing of gene expression, the nine HCC cell
lines were treated with 1 μM 5-aza-dC (Sigma-Aldrich,
St. Louis, MO, USA) to inhibit DNA methylation. Cells
(1.5 × 106) were cultured for 6 days with medium
changes on days 1, 3, and 5. On day 6, the cells were
harvested, RNA was extracted, and RT-PCR was
performed as described above.
Western blotting analysis
Cultured cells were washed twice with phosphate-
buffered saline and lysed by lithium dodecyl sulfate
(LDS) buffer (Invitrogen). Protein lysates were resolved
on 10% SDS polyacrylamide gel, electrotransferred to
polyvinylidene fluoride membranes using iBlot Gel
Transfer Device (Invitrogen) and blocked in 5% nonfat
Table 1 Expression array analysis of the 68-year-old
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4°C with a rabbit anti-DCDC2 antibody (ab106283;
Abcam plc, Cambridge, UK) followed by peroxidase-
conjugated secondary antibodies. As a control, a mouse
monoclonal anti-beta-actin antibody (Abcam plc,) was
used. Signals were detected by enhanced chemilumines-
cence (Lumivision PRO HSII, Aisin Seiki Co., LTD,
Kariya, Japan).
Immunohistochemistry
We investigated DCDC2 protein expression by immuno-
histochemistry in the same samples analyzed by the ar-
rays and in 38 HCCs whose samples were available in a
well-preserved condition. Cut sections were prepared
from formalin-fixed and paraffin-embedded tissues for
DCDC2 staining. Samples were treated with 3% H2O2 to
inhibit endogenous peroxidase, and then subjected to
antigen retrieval using 10 mM citrate buffer five times at
95°C for 10 min. Sections were incubated with Histofine
SAB-PO(R) (Nichirei, Tokyo, Japan) for 10 min, to limit
non-specific reactivity, and then incubated with DCDC2
antibody produced in rabbit (ab106283; Abcam plc) di-
luted 1:2000 in ChemMatet antibody diluent (Dako) for
12 h. All stains were developed for 15 min using liquid
diaminobenzidine (DAB) as the substrate (Nichirei). We
determined staining properties setting vessels as integral
control, and made a comparison of DCDC2 expression
between HCC tissues and corresponding non-cancerous
tissues. To avoid being subjective, specimens were ran-
domized and coded before analysis, which was con-
ducted by two independent observers, who evaluated all
specimens at least twice within a given interval to
minimize intra-observer variation.
Statistical analysis
Continuous variables are expressed as medians (range)
and comparisons were made using the Mann Whitney U
test. Categorical variables were compared using χ2 tests
or Fisher’s exact tests, where appropriate. Overall sur-
vival rates were analyzed by Kaplan-Meier and log-rank
tests. All statistical analyses were performed using JMP
software version 9.0.2 (SAS International Inc., Cary,
NC, USA). The level of statistical significance was set at
P < 0.05.
Results
Results of expression, SNP, and methylation-arrays
To identify novel tumor–related genes in HCC, we first
searched for genes with decreased expression in HCC
samples compared with corresponding normal tissue.
According to the expression array results, DCDC2 was
strongly downregulated in HCC tissue. The decreased
values (log 2 ratio) were −2.2 in a point of the expression
array chip (Table 1).We confirmed reduced expression of DCDC2 mRNA
in tumor tissue by semi-quantitative RT-PCR in the case
whose samples were used for the array analysis
(Figure 1a).
Next, we checked the results of the SNP array. We
observed deletions in 3q, 8p, 11q, 12p, 12q, 16p, 17p,
19p, and X chromosomes, and chromosomal gain in 1q,
3q, 11q, 12p, and 12q. The copy number of chromosome
6, which contains DCDC2, did not show any deletions
and amplifications (Figure 1b). Also, we looked for de-
tailed data of the SNP array at the DCDC2 gene locus at
6p22.1, and found 29 SNPs. Twelve of these 29 SNPs
showed a heterozygous AB allele in both the non-
cancerous and cancerous samples (Table 2). These re-
sults suggest that the DCDC2 gene locus retained
biallelically.
We subsequently checked the results of the methyla-
tion array: the continuous β-values were 0.846 for tumor
tissue versus 0.212 for normal tissue, indicating high
methylation in HCC sample (Table 3). Using MSP, we
confirmed hypermethylation in this gene in the tumor
tissue obtained from the 68-year-old woman whose
DNA was used for the methylation array (Figure 1c).
These results implied that DCDC2 expression decreased
without LOH, possibly because of hypermethylation at
the promoter region.
Effects of inhibiting methylation on DCDC2 expression in
nine HCC cell lines
To confirm that promoter hypermethylation led to silen-
cing of DCDC2 expression, we checked the mRNA ex-
pression of the gene before and after 5-aza-dC treatment
of nine HCC cell lines. The expression of DCDC2 in five
of these lines, HLE, HLF, HuH1, HuH2 and PLC/PRF/5,
was clearly reactivated by 5-aza-dC treatment, as shown
by semi-quantitative RT-PCR (Figure 2a).
MSP and UNMSP of nine HCC cell lines and one HCC case
Then, we designed primers for methylation-specific
(MSP) and non-methylation-specific PCR (UNMSP) and
checked the methylation status of nine HCC cell lines.
For MSP, we obtained bands of appropriate size in lanes
containing HLE, HLF, HuH1, HuH2, HuH7, PLC/PRF/5
samples, while in UNMSP, appropriate bands were
Figure 1 Results of experiments from a specimen from a 68-year-old woman. (a) Semi-quantitative RT-PCR showed downregulation of
DCDC2 in the tumor sample compared with corresponding normal tissue. (b) Copy number analysis of chromosome 6 by SNP array in the HCC
sample did not show any deletion or amplification on 6p22.1, the DCDC2 locus. (c) MSP showed promoter hypermethylation in the tumor
sample alone.
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We subsequently identified complete methylation in
HuH2, partial methylation in HLE, HLF, HuH1, HuH7
and PLC/PRF/5, and no methylation in HepG2, Hep3B
and SK-Hep1.
Sequence analysis
To confirm that MSP amplification was correctly performed,
we executed sequence analysis of the DCDC2 promoter
region in HuH2 and SK-Hep1 cells. Almost all CpG dinu-
cleotides in HuH2 were methylated, while those of
SK-Hep1 were unmethylated (Figure 3). These results
verified the accuracy of MSP and UNMSP.Table 2 Results of SNP signal at the DCDC2 gene locus
Probe set ID Chromosome Physical position N
SNP_A-2175183 6 24175005 A
SNP_A-1934540 6 24175527 A
SNP_A-2079666 6 24202016 A
SNP_A-1920269 6 24202874 A
SNP_A-2242966 6 24227520 A
SNP_A-1825242 6 24238542 A
SNP_A-4233820 6 24241681 A
SNP_A-2042383 6 24317865 A
SNP_A-2136345 6 24330431 A
SNP_A-4215128 6 24330575 A
SNP_A-4242164 6 24353402 A
SNP_A-1870108 6 24356599 A
SNP single nucleotide polymorphism, DCDC2 doublecortin domain-containing 2.MSP and UNMSP of normal and tumor tissues from 48
HCC patients
Overall, 41 of the 48 (85.4%) tumor samples displayed
DCDC2 promoter hypermethylation, whereas only 9 of
48 samples showed hypermethylation in the normal
samples (Figure 4a). Thus, hypermethylation of DCDC2
was significantly more frequent in tumor tissues (P < 0.001).
Four representative cases of MSP and UN-MSP status are
shown in Figure 4b.
Real-time quantitative RT-PCR analysis of 48 HCC patients
We also examined the expression levels of DCDC2
mRNA by real-time RT-PCR in the 48 analyzed cases,ormal call Confidence Tumor call Confidence
B 0.007813 AB 0.023438
B 0.007813 AB 0.007813
B 0.015625 AB 0.015625
B 0.0625 AB 0.132813
B 0.007813 AB 0.007813
B 0.023438 AB 0.0625
B 0.125 AB 0.0625
B 0.023438 AB 0.007813
B 0.007813 AB 0.007813
B 0.015625 AB 0.132813
B 0.047363 AB 0.02832
B 0.0625 AB 0.039063











Normal 0.212 7096 5569 1527 3.68E-38
Chr6p22.1
Tumor 0.846 9684 1399 8285 3.68E-38
HCC hepatocellular carcinoma, DCDC2 doublecortin domain-containing 2.
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vided by that of GAPDH for each sample. The DCDC2
expression index was calculated as the value of the
tumor tissue expression level divided by that of the ex-
pression level of the adjacent normal tissue. With regard
to the correlation between methylation status and ex-
pression index, hypermethylated cancerous tissues had
significantly lower DCDC2 expression index than other
tissue examined (P = 0.048; Figure 5a). However, methy-
lation in normal tissue did not show significant differ-
ence in expression index (P = 0.153; Figure 5b).
Western blotting
Evaluation by western blotting confirmed DCDC2 pro-
tein expression after 5-aza-dC treatment in HuH2 and
SK-Hep1 cells was consistent with that of RT-PCR. The
expression of DCDC2 in the cells was also reactivated by
the treatment in HuH2 cells that were completely meth-
ylated (Figure 6).
Immunohistochemical staining of DCDC2
In the 24 (63.1%) of 38 cases that underwent immu-
nohistochemical staining, the cancerous components
showed reduced DCDC2 protein expression compared
with adjacent non-cancerous tissue. In 18 of 31 methyl-
ated cases, and in six of seven unmethylated cases, theFigure 2 Results of Semi-quantitative RT-PCR and MSP in nine HCC ce
expression in five (HLE, HLF, HuH1, HuH2 and PLC/PRF/5) of nine HCC cell
methylation in HLE, HLF, HuH1, HuH7 and PLC/PRF/5, and no methylationcancerous tissues showed downregulated DCDC2, and
there was no significant relationship between methyla-
tion status and DCDC2 protein expression, suggesting
that there could be other silencing mechanisms involved
in HCC (Figure 7).
Correlation between promoter hypermethylation status
of DCDC2 gene and clinicopathological characteristics in
48 HCC patients
We analyzed the correlation between the hyperme-
thylation status of DCDC2 and clinicopathological fea-
tures of the 48 HCC patients. Whereas no notable
association between the methylation status and clinico-
pathological variables was detected (data not shown),
the methylated cases showed poorer prognosis of overall
survival than the unmethylated cases (P = 0.048;
Figure 8).
Discussion
Recent studies have investigated the relationship between
carcinogenesis and DNA methylation in different cancer
types [28-30]. Methylation in a number of genes in
HCC has also been investigated worldwide [31-34].
However, it is unknown whether methylated genes in
HCCs are associated with gene expression, or prognosis
of the patients.ll lines. (a) Semi-quantitative RT-PCR showed reactivation of DCDC2
lines. (b) MSP showed complete methylation in HuH2, partial
in HepG2, Hep3B and SK-Hep1.
Figure 3 Sequence analysis of bisulfate-treated DNA in the DCDC2 promoter region. Methylation status of the 22 CpG islands in the six
clones by TA cloning method between −100 and +150 from the transcription initiation site of DCDC2 exon 1 is shown. Closed circles represent
methylated CpG islands; open circles indicate unmethylated CpG islands. The CpG islands in the promoter region in HuH2 cells were abundantly
methylated, whereas CpG islands in SK-Hep1 cells were abundantly unmethylated. The middle figures in the sequence analysis show the results
at the CpG islands between 41 and 73 corresponding to the boxes of the lower figure. The Cs indicate methylated CpG islands. The Ts were
converted from C by bisulfite treatment, and indicate unmethylated CpG islands. These results verified the accuracy of MSP and UNMSP in
upper figures.
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tion of the prognosis of patients who undergo hepatec-
tomy for HCC, we developed a double combination array
analysis consisting of expression array and SNP array ana-
lysis, and have reported several genes associated with
hepatocarcinogenesis [12-17]. Our experiment proves that
these genes were hypermethylated in HCC tumor tissues,
resulting in decreased expression and poorer prognosis,
and we realized the double combination array analysis was
an efficient procedure to identify new cancer-related genes
via an epigenetic mechanism. However, this procedure re-
quired validation in HCC specimens on the basis that the
downregulation of these genes occurred by methylation of
promoter regions. To ensure the involvement of gene
methylation, we developed a triple combination array ana-
lysis that consists of expression array, SNP array, and
methylation array analysis, and reported a new tumor sup-
pressor gene using this procedure [18].In the current study, we identified DCDC2 as a candi-
date tumor suppressor gene in HCC using triple com-
bination array analysis. The promoter region of this gene
was hypermethylated in many cancer tissues but only in
a few normal tissues. The expression of DCDC2 in tumor
tissues was decreased in methylated cases (P = 0.048). The
overall survival of the patients with DCDC2 methylation
was significantly worse than those without methylation
(P = 0.048).
DCDC2 has been reported as a gene related with dys-
lexia [21-24]. DCDC2 protein is considered to have im-
portant roles in neural migration and construction of
microtubules [19-21]. Massinen et al. showed down-
regulation of DCDC2 expression enhanced Wnt signal-
ing, which is important in neuronal development [35].
Moreover, it is known that aberrant activation of the
Wnt pathway is associated with human malignancies,
including HCC [36,37]. Therefore, it could be hypothesized
Figure 4 Results of MSP in 48 HCC cases. (a) Methylation status in 48 primary HCC samples. Forty-one of 48 (85.4%) cancer tissues showed
hypermethylation of DCDC2, while only 9 of 48 (18.7%) cases showed hypermethylation in adjacent normal tissues. (b) Four representative cases
showing hypermethylation of the promoter region of DCDC2 in tumor tissues without methylation in normal tissues.
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of its protein product to cause activation of the Wnt path-
way and worsen the prognosis of HCC patients. To sup-
port this hypothesis, various studies investigated secreted
frizzled-related protein 1 (SFRP1) in HCC [38-41], and
Kaur P et al. indicated SFRP1 expression was down-Figure 5 Results of quantitative RT-PCR in 48 HCC cases.
(a) Expression levels of DCDC2 mRNA examined by RT-PCR in 48 cases.
The expression index [(DCDC2-tumor) × (GAPDH-normal)/(DCDC2-
normal) × (GAPDH-tumor)] was calculated for all 48 cases.
Expression index in methylated cases were significantly lower than
unmethylated cases (P = 0.048). (b) Methylation in normal tissue did
not show significant difference in expression index (P = 0.153).regulated by methylation resulting in activation of the
Wnt pathway and contributing to increased HCC cell
growth and proliferation [41]. Therefore, DCDC2 might
play a role in HCC in similar way to SFRP1.
One of the limitations of this method is that we can
obtain array information from only one pair of resected
specimens at a time. However, we identified DCDC2 by
triple combination array analysis. Thus, we investigated
this gene in 48 resected HCC specimens and proved the
impact of methylation in cancer tissues. The relevance
of DCDC2 in the tumorigenesis of HCC could therefore
be considered as universal. Another limitation is that theFigure 6 Western blotting analysis showed reactivation of
DCDC2 protein by 5-aza-dC treatment in HuH2 cells that were
completely methylated, whereas reactivation was not observed
in SK-Hep1 cells that were completely unmethylated.
Figure 7 Representative finding of immunohistochemical
staining of DCDC2 in a resected sample. Strong staining was
observed in the cytoplasm of non-cancerous cells, whereas weak
staining was present in tumor cells (upper picture: magnification
40×, lower picture: magnification 200×).
Figure 8 Overall survival stratified by methylation status of
DCDC2. Methylated cases of tumor tissues were significantly
correlated with a worse prognosis compared with that of
unmethylated cases (P = 0.048).
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methylation status did not show significant association.
We consider that the methylation is not the only
mechanism that regulates the protein expression.
Other mechanisms such as histone deacetylation or
post-transcriptional regulation by microRNAs might
play a role in regulation of DCDC2 protein expression
[42,43]. However, our results showed the contribution
of methylation in mRNA expression and prognosis
after surgery.
Taken together, the methylation of DCDC2 could be a
prognostic marker after surgical resection of HCC. Fur-
thermore, decitabine has become a therapeutic agent for
patients with myelodysplastic syndrome (MDS) by DNA
hypomethylation [44]. It is considered that p15 and
other methylated genes may be therapeutic targets of
the DNA methylation-inhibitory activity of decitabine in
MDS [45]. In the future, it might be applied in the clin-
ical setting for HCC patients who have methylated
DCDC2 in their tumor tissue.Conclusions
In conclusion, our triple combination array analysis
detected DCDC2 as a candidate tumor suppressor gene
in HCC. Additional investigations of the function of this
gene in carcinogenesis are required to confirm this gene
as a bona fide tumor suppressor. According to our clin-
ical data from 48 HCC specimens, the extent of pro-
moter hypermethylation for this gene correlated with
overall survival. Further studies will be required to
evaluate the effect of DCDC2 re-expression in HCC cells
by a methylation inhibitor. If re-expression with such an
agent can inhibit tumor growth, this may represent a
key line of therapy for advanced HCC tumors.Abbreviations
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